title: [A case of triple negative recurrent breast cancer successfully treated with capecitabine+docetaxel combination chemotherapy].
abstract: A 73-year-old woman underwent pectoralis-preserving mastectomy for left breast cancer (papillotubular carcinoma, f, T2, ly0, v0, N1 (21/21), T2N1M0 (Stage IIB), ER (-), PgR (-), HER2 (-)) in August 2004. It was called a triple negative breast cancer. She received systemic chemotherapy using AC followed by paclitaxel. In February 2006 (disease- free interval of one year and five months), skin and chest wall recurrences in the left breast were revealed. Systemic chemotherapy using capecitabine (1,800 mg/body/day) monotherapy resulted in PD after 4 courses. Subsequently, treatment with capecitabine+cyclophosphamide combination therapy resulted in PD after 6 courses. Since November 2006, treatment with capecitabine+docetaxel combination chemotherapy was initiated. Each course consisted of capecitabine at a dosage of 1,800 mg/body/day for 2 weeks and docetaxel at a dosage of 60 mg/body (day 8 only) followed by withdrawal for 1 week. After 3 courses, a marked response was seen, and a total of 6 courses were performed. No serious side effect was revealed, and a marked response has been maintained. It is suspected that capecitabine+docetaxel combination therapy is useful for a triple negative recurrent breast cancer which is refractory to systemic chemotherapy.
authors.affiliation: Dept. of Surgery, Matsuyama Shimin Hospital, Japan.
authors.forename: Yasuki
authors.initials: Y
authors.lastname: Hachisuka
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kamei
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Umeoka
authors.forename: Masashi
authors.initials: M
authors.lastname: Kimura
authors.forename: Masashi
authors.initials: M
authors.lastname: Uomoto
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Hatano
authors.forename: Hiroki
authors.initials: H
authors.lastname: Johira
authors.forename: Shigeru
authors.initials: S
authors.lastname: Yunoki
authors.forename: Naomi
authors.initials: N
authors.lastname: Kawata
authors.forename: Ryouhei
authors.initials: R
authors.lastname: Watanabe
authors.forename: Katsusuke
authors.initials: K
authors.lastname: Ohmori
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Miyata
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001943:Breast Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D012008:Recurrence; D043823:Taxoids / Q000627:therapeutic use*; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D014408:Biomarkers, Tumor; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D005472:Fluorouracil